Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Rev-ving up ADCC

In addition to its own antiproliferative effects, a growing body of evidence suggests that Revlimid lenalidomide from Celgene Corp. is capable of enhancing the antibody-dependent cell-mediated cytotoxicity activity of antibodies such as Rituxan rituximab. Earlier this month, CELG and Seattle Genetics Inc. each presented data at the American Society of Hematology meeting supporting the idea that Revlimid may have synergies with a variety of

Read the full 642 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers